Dermaliq Therapeutics, a newly formed Wilmington, Delaware-based pharmaceutical development company, raised USD 15m in Series A financing.
The round was led by 3E Bioventures Capital, joined by Beijing Whale Technology Corporation Ltd. Dermaliq’s existing shareholder Novaliq has transferred, and licensed Intellectual Property (IP) related to the field of dermatology to Dermaliq. Karen Liu of 3E Bioventures Capital will join Dermaliq’s Board of Directors.
Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The proprietary technology now owned by Dermaliq, called hyliQ™, is designed to allow cutaneous drug delivery with bioavailability. The technology enables the development of effective liquid drug products with exceptional cosmetic properties.
The proceeds will be used to conduct three Phase 1/2a clinical dermatology programs with the goal to demonstrate safety and efficacy and to advance this novel skin care drug category to market to improve the lives of millions of patients:
- DLQ01 is a liquid drug candidate for the topical treatment of female and male androgenetic alopecia, targeting the prostamide E2 (PGE2) receptor in hair bulbs through specific follicular drug delivery.
- DLQ02 is a novel and liquid topical calcineurin inhibitor drug therapy for plaque psoriasis, particularly in difficult to treat areas.
- DLQ03 is a broad-spectrum liquid antibiotic drug candidate that targets topical treatment of bacterial skin and soft tissue infections, including the reduction of antibiotic-resistant strains.
The company has demonstrated proof-of-principle for enhanced topical drug delivery using hyliQ™ in nonclinical models for all three applications.
